Executive SummarySigns agreement with privately-held Tanox Biosystems for joint development of monoclonal antibody-based products to treat allergic reactions mediated by immunoglobulin E. Ciba-Geigy will pursue clinical development of anti-IgE monoclonal antibodies designed by Tanox. In return, Houston-based Tanox will receive financial payments and share manufacturing and promotion rights to resulting products.
You may also be interested in...
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.